Skip to content

The Effect of Turmeric and Chicory seeds on Non-alcoholic fatty liver disease patients(NAFLD)

The Effect of Turmeric and Chicory seeds separately and together on Metabolic Condition and Oxidative ,Inflammatory Indices and Fetuin-A on Non-alcoholic fatty liver disease patients(NAFLD)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201406183664N12
Enrollment
84
Registered
2015-01-18
Start date
2014-12-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Fatty liver

Interventions

Intervention 1: Intervention Group: 500 mg Turmeric, 6 tablets/day for 12 weeks. Intervention 2: Intervention Group: 9 g/ day Chicory seeds for 12 weeks. Intervention 3: Intervention Group: 500 mg Tu
Treatment - Drugs
Placebo
Intervention Group: 500 mg Turmeric, 6 tablets/day for 12 weeks
Intervention Group: 9 g/ day Chicory seeds for 12 weeks
Intervention Group: 500 mg Turmeric(6 tablets/day) and ( 9 g/day) Chicory seeds for 12 weeks
Placebo groups: Placebo,6 tablets/day for12 weeks

Sponsors

Vice Chancellor for Research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Liver steatosis on Sonographic image; ?Female: 20-50 years old and Male: 20-60 years old; 24.9=BMI>40. Exclusion criteria: Alcohol intake; Gestation or Lactation or Menopause; Lose Weight Diet; Anemia; Very active or Athleta; Cardiovascular disease; Pulmonary disease; Gastrointestinal disease; Renal disease; Liver transplantation and other liver diseases and chronic or acute liver disease (Hepatitis A,B, ...); Bilious impairments; Biliary Stone; Kidney Stone; Autoimmune disease; Cancers; Inheritance diseases; Using drugs like hepatotoxic drugs; Anticoagulant drugs; Vitamin A E C and omega 3 suplement; and Oral Contraceptive drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Liver Enzyme (ALT,AST,ALP?GGT). Timepoint: Beginning and end of the intervention. Method of measurement: Spectrophotometry.;Metabolic condition. Timepoint: Beginning and end of the intervention. Method of measurement: FBS, TC, TG and HDL Spectrophotometry, Insulin ELISA.;Oxidative Indicies. Timepoint: Beginning and end of the intervention. Method of measurement: TAC Spectrophotometry, MDA Thiobarbituric acid.;Inflammatory Indicies. Timepoint: Beginning and end of the intervention. Method of measurement: hs-CRP Immuno Turbidimetry,TNFa and IL-6 ELISA.;Fetuin A. Timepoint: Beginning and end of the intervention. Method of measurement: Fetuin A by ELISA.;Added at 2016-01-24: ICAM1. Timepoint: Added at 2016-01-24: end of the study. Method of measurement: Added at 2016-01-24: ELISA.

Secondary

MeasureTime frame
Anthropometry. Timepoint: Begining and end of intervention. Method of measurement: Scale and Meter.;Energy and Nutrient intake. Timepoint: Beginning, sixth week and end of the intervention. Method of measurement: Dietary record.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAida Ghaffari

Nutrition Faculty, Tabriz University of Medical Sciences

ai_gh_nutry83@yahoo.com+98 41 3335 7581

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026